Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists

Hormone and Metabolic Research

Volumn 42, Issue 6, 2010, Pages 458-465

  Schupp, N ^a   Queisser, N ^a   Wolf, M ^a   Kolkhof, P ^b   Barfacker L ^b   Schafer S ^b   Heidland, A ^a   Stopper, H ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Micronuclei; Oxidative stress; Spironolactone; Superoxide

Indexed keywords

ALDOSTERONE; BR 4628; CATALASE; ETHYL 5 ACETYL 2,6 DIMETHYL 4 (2 METHYL 4 OXO 4H CHROMEN 8 YL) 1,4 DIHYDROPYRIMIDINE 3 CARBOXYLATE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; TEMPOL; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMOSOME DAMAGE; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG SELECTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; KIDNEY CELL; MICRONUCLEUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CELLS, CULTURED; CHROMOSOMES; COMET ASSAY; CYTOPROTECTION; DNA BREAKS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HORMONE ANTAGONISTS; KIDNEY; MICRONUCLEUS TESTS; MIFEPRISTONE; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; SWINE;

SUIDAE;

EID: 77952893620     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1243253     Document Type: Article

References (55)

1. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007 113 267-278
2. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005 186 1-20
3. Good DW. Nongenomic actions of aldosterone on the renal tubule. Hypertension 2007 49 728-739
4. Boldyreff B, Wehling M. Rapid aldosterone actions: from the membrane to signaling cascades to gene transcription and physiological effects. J Steroid Biochem Mol Biol 2003 85 375-381
5. Funder JW. Minireview: Aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 2006 147 5564-5567
6. Funder J, New MI. Low renin hypertension (LRH): shades of John Laragh. Trends Endocrinol Metab 2008 19 83
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006 48 2293-2300
8. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993 20 296-298
9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: Diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 117 e510-e526
10. Krug AW, Ehrhart-Bornstein M. Adrenocortical dysfunction in obesity and the metabolic syndrome. Horm Metab Res 2008 40 515-517
11. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008 19 88-90
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 709-717
13. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 1309-1321
14. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006 100 9-16
15. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006 119 912-919
16. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008 19 1459-1462
17. Nishiyama A, Hitomi H, Rahman A, Kiyomoto H. Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers. J Pharmacol Sci 2009 109 1-6
18. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005 46 45-51
19. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005 112 1435-1443
20. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008 52 486-493
21. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2002 112 479-486
22. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001 92 2462-2470
23. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 2005 23 240-255
24. Schupp N, Schmid U, Rutkowski P, Lakner U, Kanase N, Heidland A, Stopper H. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol 2007 292 F1427-F1434
25. Schmid U, Stopper H, Schweda F, Queisser N, Schupp N. Angiotensin II induces DNA damage in the kidney. Cancer Res 2008 68 9239-9246
26. Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem 2006 17 21-28
27. Leite-Dellova DC, Oliveira-Souza M, Malnic G, Mello-Aires M. Genomic and nongenomic dose-dependent biphasic effect of aldosterone on Na+/H+ exchanger in proximal S3 segment: role of cytosolic calcium. Am J Physiol Renal Physiol 2008 295 F1342-F1352
28. Patni H, Mathew JT, Luan L, Franki N, Chander PN, Singhal PC. Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. Am J Physiol Renal Physiol 2007 293 F1065-F1071
29. Leckie C, Chapman KE, Edwards CR, Seckl JR. LLC-PK1 cells model 11 beta-hydroxysteroid dehydrogenase type 2 regulation of glucocorticoid access to renal mineralocorticoid receptors. Endocrinology 1995 136 5561-5569
30. Kolkhof P, Hillisch A, Schäfer S. Severe early-onset hypertension induced by a mineralocorticoid receptor (MR) gain-of-function mutation: differential effects of steroidal versus non-steroidal antagonists. Eur Heart J 2007 28 769
31. Yang H, Acker J, Chen A, McGann L. In situ assessment of cell viability. Cell Transplant 1998 7 443-451
32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000 132 365-386
33. Rasband WS. Image J. In. Bethesda, Maryland, USA: U. S. National Institutes of Health 19972008
34. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988 175 184-191
35. Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, Escobar P, Honma M, Kumaravel TS, Nakajima M, Sasaki YF, Thybaud V, Uno Y, Vasquez M, Hartmann A. Fourth International Workgroup on Genotoxicity testing: results of the in vivo Comet assay workgroup. Mutat Res 2007 627 31-35
36. Brendler-Schwaab S, Hartmann A, Pfuhler S, Speit G. The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis 2005 20 245-254
37. Maluf SW. Monitoring DNA damage following radiation exposure using cytokinesis-block micronucleus method and alkaline single-cell gel electrophoresis. Clin Chim Acta 2004 347 15-24
38. Decordier I, Kirsch-Volders M. The in vitro micronucleus test: from past to future. Mutat Res 2006 607 2-4
39. Calo LA, Pagnin E, Davis PA, Armanini D, Mormino P, Rossi GP, Pessina AC. Oxidative Stress Related Proteins in a Conn's Adenoma Tissue Relevance for Aldosterone's Prooxidative and Proinflammatory Activity. J Endocrinol Invest 2009 July 21 [Epub ahead of print]
40. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008 149 1009-1014
41. Yu L, Bao HF, Self JL, Eaton DC, Helms MN. Aldosterone-induced increases in superoxide production counters nitric oxide inhibition of epithelial Na channel activity in A6 distal nephron cells. Am J Physiol Renal Physiol 2007 293 F1666-F1677
42. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T, Matsubara H. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 2008 31 363-375
43. Mathew JT, Patni H, Chaudhary AN, Liang W, Gupta A, Chander PN, Ding G, Singhal PC. Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol 2008 295 F73-F81
44. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008 12 233-242
45. Yoshida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Izumi Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005 28 447-455
46. Liew D, Krum H. Aldosterone receptor antagonists for hypertension: what do they offer? Drugs 2003 63 1963-1972
47. Kushibiki M, Yamada M, Oikawa K, Tomita H, Osanai T, Okumura K. Aldosterone causes vasoconstriction in coronary arterioles of rats via angiotensin II type-1 receptor: influence of hypertension. Eur J Pharmacol 2007 572 182-188
48. Gauer S, Segitz V, Goppelt-Struebe M. Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. Nephrol Dial Transplant 2007 22 3154-3159
49. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001 345 1689-1697
50. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens 2008 26 613-621
51. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007 66 607-618
52. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004 136 1227-1235
53. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002 106 927-932
54. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 2008 72 (Suppl A) A31-A37
55. Andreassi MG. DNA damage, vascular senescence and atherosclerosis. J Mol Med 2008 86 1033-1043